NCT00658619 - Safety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geographic Atrophy Due to Age-related Macular Degeneration (AMD) | Biotech Hunter

Enrollment

119

Participants

Timeline

Start Date

May 1, 2008

Primary Completion Date

June 1, 2010

Study Completion Date

April 8, 2011

Conditions

Macular Degeneration

Interventions

DRUG

400 µg Brimonidine Tartrate Implant

400 µg brimonidine tartrate implant in the study eye on Day 1 and Month 6.

DRUG

200 µg Brimonidine Tartrate Implant

200 µg brimonidine tartrate implant in the study eye on Day 1 and Month 6.

OTHER

Sham (no implant)

Sham in one or both eyes on Day 1 and Month 6.

Trial Locations (7)

Abilene

Sydney

Karlsruhe

Udine

Makati City

Coimbra

Seoul